As some of you may have heard/read, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a directive to doctors to review HRT prescriptions with their patients when they come in to clinic.
This directive is based purely on the recent report in The Lancet, a weekly peer-reviewed general medical journal.
There are still many questions over the research from the University of Oxford, including why has it been given so much credence when it is not new data. The British Menopause Society (BMS) has written to the MHRA to raise concerns and ask for some answers.
You can read the letter by clicking on this link.
‘The British Menopause Society is writing to raise serious concerns about the recommendations in the drug safety alert ‘Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping’, published by the MHRA on 30 August 2019.’